LeCancer.fr (@LeCancerFr) header
LeCancer.fr (@LeCancerFr) profile picture
Paris
Joined May 2012
Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)Photo by LeCancer.fr (@LeCancerFr)
Epuisant 😅 mais enthousiasmant 😁 Le groupe #CBNPC révise la version de travail du référentiel 2024 ##ARISTOT! Une coopération des équipes d'oncologie thoracique des 4 CHU et 2 CLCC de @auvergnerhalpes. @CHUdeLyon @ChuSaintEtienne @CHUClermontFd @CLCCLeonBerard #NovembrePerle
1
6
13
1,289
Bienvenu aux participants et partenaires de l’édition 2018 des référentiels AURA d’oncologie thoracique #refAURA18 #lyon
8
5
Guidelines on thoracic cancers. 2017 edition #Lyon
5
7
Que hagas RT no cura,cierto,pero visibiliza,sensibiliza,desdramatiza y hoy sirve de apoyo a #mujeres pacientes de #cáncerginecológico – at San Sebastián de los Reyes, España
1
29
2
27
#JournéeEuropéennedelaProstate: le 20/09, l'AFU organise un chat Facebook pr tt savoir sur le cancer de la #prostate. Posez vos questions!
ALK resistance overview in 2 slides #ESMO17
1
8
1
4
The largest study to date of Immune-checkpoint inhibitors associated interstitial lung disease. #NSCLC #Melanoma erj.ersjournals.com/content/…
5
6
another potential mechanism of resistance. RHOB confers resistance to EGFR-TKI in NSCLC via AKT. EMBO Mol Med. onlinelibrary.wiley.com/doi/…
1
1
BRAF V600 NSCLC: combo dabra/trametinib the best deal for efficacy but take care to high toxicity (50% G3-4; 20% discontinuation for tox)
2
5
2
6
LeCancer.fr retweeted
#ESMO17 @Annals_Oncology immune targets to enhance cancer immunotherapy Marabelle et al @GustaveRoussy doi.org/10.1093/annonc/mdx17…
2
34
4
55
Again alectinib wins (vs. Chemo in 2L+ including crizo); but who doubted ?
#ESMO17 better cns control with alectinib
9
3
Don't forget: liquid biopsies are not only in blood ! @JulienMazieres
Excellent discussion of IFCT CLINIVO data today. Special thanks to IFCT investigators and IFCT team for the effort!#ESMO17 #IFCT
6
6
LeCancer.fr retweeted
Great review on clinical application of liquid biopsy for management of NSCLC by Dr Wang #ESMO17 #liquidgold #ctDNA
6
4
IO for #NSCLC is a revolution for all the physicians but only for a minority of pts when non selected. #ESMO17
1
6
9
Targetting FGFR is interesting in mesothelioma and well-tolerated. Looking forward further trials
Great presentation @GerardZalcman @IFCTlung #ESMO2017 new era for #mesothelioma patients
3
5
Pembro in #mesothelioma. Very nice results from the Swiss registry. Esp. in good PS, sarcomatoid & PDL1 pos tumors #esmo17
2
26
3
30